DIABETES INSIPIDUS - Treatment
Treatment of central diabetes insipidus depends to a large extent on the severity of the hormone deficiency. In patients in whom the deficiency is only partial, chlorpropamide will potentiate the effect of ADH on the renal tubule. However, hypoglycemia may result, particularly if the dose of chlorpropamide exceeds 250 mg per day. Patients with more complete hormone deficiency require ADH replacement therapy. Long-acting Pitressin Tannate in Oil (warmed and shaken thoroughly), in doses of 5 units intramuscularly every 48 to 72 hours, has been the standard treatment. More recently a synthetic analogue, 1-desamino-8-D-arginine vasopressin (DDAVP), has become the treatment of choice. Devoid of significant pressor activity, DDAVP can be conveniently administered by nasal insufflation in doses of 5 to 10 u.g every 12 to 24 hours. No specific treatment is available for patients with nephrogenic diabetes insipidus, but reduction of solute load by salt restriction and administration of thiazide diuretics will reduce the polyuria.
- THYROTOXICOSIS (HYPERTHYROIDISM)
- PHYSIOLOGICAL REGULATION OF ADH SECRETION
- DIABETES INSIPIDUS - Diagnosis
- THYROTOXICOSIS (HYPERTHYROIDISM) - Thyroiditis
- THYROTOXICOSIS (HYPERTHYROIDISM) - Toxic nodular Goiter
- DIABETES INSIPIDUS - Etiology
- THYROID PHYSIOLOGY
- THYROID FUNCTION TESTS
- THYROTOXICOSIS (HYPERTHYROIDISM) - Graves Disease
- DIABETES INSIPIDUS - Treatment